Editorial

Insights & Research

Deep-dives, opinion, and science-led commentary on immuno-oncology, biomarkers, and precision medicine, from the ImmunoMark editorial team and guest contributors.

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
All Biotech Events & Conferences Industry Insights Oncology Biomarkers Regulatory Affairs
Featured

Latest Articles

All

Personalised Cancer Vaccines: The Biomarkers That Decide Who Benefits

Intismeran autogene has delivered the first positive phase 3 for an individualised neoantigen therapy, while autogene cevumeran's colorectal trial was…

swastik98 Oct 2026
All

Immune-Related Adverse Events as a Biomarker: What Toxicity Tells Us About Response

irAEs often track with response to checkpoint inhibitors, but immortal time bias inflates the link. Here is what the evidence…

swastik98 Oct 2026
All

Bispecific Antibodies in Solid Tumours: Biomarkers, Toxicity & the Pipeline

Beyond T cell engagers: how receptor-targeting and PD-1 x VEGF bispecific antibodies are selected, what their toxicity looks like, and…

swastik98 Oct 2026
All

LDT vs IVD: What Changed for Oncology Biomarker Tests

The FDA's 2024 LDT rule was vacated in March 2025 and formally rescinded in September 2025. Here is where US…

swastik98 Oct 2026
All

ASCO 2027: A Clinical Data Planner for Biomarker & CDx Teams

How biomarker, CDx, CRO and diagnostics teams should read late-stage clinical readouts in the June data season: pre-specified vs exploratory…

swastik98 Oct 2026
All

Claudin 18.2, B7-H3 & TROP2: Biomarker Strategies for the Next ADC Wave

Claudin 18.2 has a 75% companion diagnostic cut-off for zolbetuximab while its lead ADC succeeded at 25%, and B7-H3 ADCs…

swastik98 Oct 2026

Join us for our Upcoming Editions

300+ senior leaders. Two streams. One agenda: advancing precision oncology.

Waitlist for Boston Edition Register for San Diego Edition Register for London Edition